Printer Friendly

Creative Biolabs Offers Various Recombinant Viruses for Gene Therapy.

M2 PRESSWIRE-August 26, 2019-: Creative Biolabs Offers Various Recombinant Viruses for Gene Therapy



New York, USA -- As a world-leading expert in gene therapy, Creative Biolabs is committed to offering high-quality and different types of recombinant virus for gene therapy research all the time, including but not limited to recombinant adeno-associated virus, recombinant adenovirus, recombinant lentivirus.

1. Recombinant Adeno-Associated Virus

In gene therapy, the recombinant adeno-associated virus (rAAV) delivers DNA to target cells with reliable safety and high efficiency in preclinical and clinical settings. Professional scientists in Creative Biolabs apply rigorous criteria that have been established for rAAV production and are able to develop various AAV serotypes and engineered strategies to support clients' projects. A series of AAV serotype products with rationally design and optimization are provided at Creative Biolabs, including AAV2, AAV5, AAV8, and AAV9 serotype vectors with distinct tissue-tropism, and long-term transgene expression, targeting specific tissues and organs to further expand their therapeutic landscape.

2. Recombinant Adenovirus

Generally, adenovirus plays a role as a gene transfer vector or oncolytic virus in cancer therapy, delivering genes with high efficiency to different cell types and allowing high expression of the recombinant protein. The coated protein modification improves the target specificity of the adenovirus to tumor cells. Equipped with high packaging capacity (up to 8 kb), high titer during production and high level of gene expression, recombinant adenovirus from Creative Biolabs is capable of infecting both non-dividing and dividing cells, without being integrated into the host chromosome, thereby ensuring the safety.

3. Recombinant Lentivirus

Recombinant lentivirus vectors are widely used in preclinical gene therapy development, including vascular diseases, diabetes mellitus, rheumatoid arthritis and different cancers, etc, characterized by an efficient infection in both dividing and nondividing cells, and a long-term gene expression. Creative Biolabs can develop first-in-class recombinant lentivirus that best fits the clients' requirements and expedites the development programs.

With the cutting-edge recombinant DNA technology at Creative Biolabs, all recombinant viruses can be generated with incorporated modifications in a specific viral gene or locus and a broad tropism allowing gene expression in various of host cells.

More information can be reached at

About Creative Biolabs

As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. With years of experience in providing one-stop preclinical development service, Creative Biolabs has built a team of expertise of solid knowledge of gene therapy, and we are fully competent in providing services for our clients. The services include but are not limited to delivery vehicles development, potency tests, safety and toxicology analysis, solutions of specific gene therapy development for diseases.

Media Contact

Company Name: Creative Biolabs

Contact Person: Candy Swift


Phone: 1-631-619-7922

Address:45-1 Ramsey Road

City: Shirley

State: New York

Country: United States



((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at on the world wide web. Inquiries to
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Presswire
Date:Aug 26, 2019
Previous Article:Abbenhuis Textiel Leading The Charge For Its Industry In The Netherlands.
Next Article:Quarterly Oil & Gas Midstream M&A Deals Review, Q2 2019.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters